The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
Open accessAbstract
Background: High levels of ketone bodies are associated with improved survival as observed with regular exercise, caloric restriction, and—most recently—treatment with sodium–glucose linked transporter 2 inhibitor antidiabetic drugs. In heart failure, indices of ketone body metabolism are upregulated, which may improve energy efficiency and increase blood flow in skeletal muscle and the kidneys. Nevertheless, it is uncertain how ketone bodies affect myocardial glucose uptake and blood flow in humans. Our study was therefore designed to test whether ketone body administration in humans reduces myocardial glucose uptake ( MGU ) and increases myocardial blood flow. Methods and Results: Eight healthy subjects, median aged 60 were randomly studied twice: (1) During 390 minutes infusion of Na‐3‐hydroxybutyrate ( KETONE ) or (2) during 390 minutes infusion of saline ( SALINE ), together with a concomitant low‐dose hyperinsulinemic–euglycemic clamp to inhibit endogenous ketogenesis. Myocardial blood flow was measured by 15 O‐H 2 O positron emission tomography/computed tomography, myocardial fatty acid metabolism by 11 C‐palmitate positron emission tomography/computed tomography and MGU by 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography. Similar euglycemia, hyperinsulinemia, and suppressed free fatty acids levels were recorded on both study days; Na‐3‐hydroxybutyrate infusion increased circulating Na‐3‐hydroxybutyrate levels from zero to 3.8±0.5 mmol/L. MGU was halved by hyperketonemia ( MGU [nmol/g per minute]: 304±97 [ SALINE ] versus 156±62 [ KETONE ], P <0.01), whereas no effects were observed on palmitate uptake oxidation or esterification. Hyperketonemia increased heart rate by ≈25% and myocardial blood flow by 75%. Conclusions: Ketone bodies displace MGU and increase myocardial blood flow in healthy humans; these novel observations suggest that ketone bodies are important cardiac fuels and vasodilators, which may have therapeutic potentials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Regulation of coronary blood flow during exercise
Duncker, D. J., & Bache, R. J. (2008) · Physiological Reviews · doi:10.1152/physrev.00045.2006 · Cited by 936
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571 · cited 1×
“Intriguingly, new data from the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial(15) have led several investigators to propose that the 2- to 3-fold increase in ketone body levels observed in type 2 diabetic patients treated with SGLT-2 inhibitors may explain the surprising and…”
ResultNutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes
Cox, P. J., Kirk, T., Ashmore, T., Willerton, K., Evans, R., Smith, A., Murray, A. J., Stubbs, B., West, J., McLure, S. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.010 · Cited by 530 · cited 1×
“Furthermore, a very recent study has shown that co-administration of glucose and 3-hydroxybutyrate esters, creating a similar metabolically favorable scenario with high insulin levels and suppressed FFAs, improves exercise performance in humans.(58) Some major drawbacks to the study design should be mentioned.”
BackgroundThe Effects of a Ketogenic Diet on Exercise Metabolism and Physical Performance in Off-Road Cyclists
Zajac, A., Poprzecki, S., Maszczyk, A., Czuba, M., Michalczyk, M., & Zydek, G. (2014) · Nutrients · doi:10.3390/nu6072493 · Cited by 184
Insulin resistance in the vasculature
Mather, K. J., Steinberg, H. O., & Baron, A. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67166 · Cited by 120
Cited by
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Mitochondrial dysfunction in pathophysiology of heart failure
Zhou, B., & Tian, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120849 · Cited by 923
Nielsen, R., Møller, N., Gormsen, L. C., Tolbod, L. P., Hansson, N. H., Sorensen, J., Harms, H. J., Frøkiær, J., Eiskjaer, H., Jespersen, N. R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036459 · Cited by 518
Self-citationLoss of Metabolic Flexibility in the Failing Heart
Karwi, Q. G., Uddin, G. M., Ho, K. L., & Lopaschuk, G. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00068 · Cited by 442
The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense
Horton, J. L., Davidson, M. T., Kurishima, C., Vega, R. B., Powers, J. C., Matsuura, T. R., Petucci, C., Lewandowski, E. D., Crawford, P. A., Muoio, D. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124079 · Cited by 364
Metadata
- Authors
- Gormsen, L. C., Svart, M., Thomsen, H. H., Søndergaard, E., Vendelbo, M. H., Christensen, N., Tolbod, L. P., Harms, H. J., Nielsen, R., Wiggers, H., Jessen, N., Hansen, J., Bøtker, H. E., & Møller, N.
- Venue
- Journal of the American Heart Association
- Published
- 2017-03
- Volume
- 6
- Issue
- 3
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2594282927
- Cited by
- 234
- References
- 7
- FWCI
- 11.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.